F. Schütz

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
F Schütz, F. Schütz, Florian Schütz, Florian Schütz
Publication record
114 papers · 2,046 citations · H-index 25

PAPERS

Update Breast Cancer 2021 Part 3 – Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel
20216 citationsauthor #9
Perimenopause and Postmenopause – Diagnosis and Interventions. Guideline of the DGGG and OEGGG (S3-Level, AWMF Registry Number 015-062, September 2020) Peri- und Postmenopause – Diagnostik und Interventionen. Leitlinie der DGGG und OEGGG (S3-Level, AWMF-Registernummer 015-062, September 2020)
202126 citationsauthor #25
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021
202162 citationsauthor #35
Update Breast Cancer 2021 Part 1 – Prevention and Early Stages
202111 citationsauthor #17
Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients
20216 citationsauthor #18
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021
202139 citationsauthor #35
Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers
20216 citationsauthor #16
AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
202124 citationsauthor #38
Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
20210 citationsauthor #38
Abstract PS1-21: Molecular fluorescence-guided surgery using Beva800 for the assessment of tumor margins during breast conserving surgery of patients with primary breast cancer (MARGIN-II)
20210 citationsauthor #4
Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients
202137 citationsauthor #23
Translationale Highlights Mamma- und Ovarialkarzinom 2019 – Immuntherapien, DNA-Reparatur, PI3K-Inhibition und CDK4/6-Therapien
20200 citationsauthor #8
Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics
202014 citationsauthor #9
Targeting the oncofetal glyco-epitope TF blocks proliferation, migration and survival of breast cancer cell lines
20200 citationsauthor #7
Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer
202013 citationsauthor #6
Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies
202019 citationsauthor #19
Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer
202029 citationsauthor #5
Update Breast Cancer 2020 Part 3 – Early Breast Cancer
202011 citationsauthor #18
Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
202046 citationsauthor #6
HER2-targeted therapy influences CTC status in metastatic breast cancer
202029 citationsauthor #10
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy – German Experts’ Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019)
20199 citationsauthor #20
Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS+EG score
201910 citationsauthor #11
Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
201915 citationsauthor #8
Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria – clinical results from 179 breast centers in Germany 2008 – 2015
20190 citationsauthor #8
Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort
20198 citationsauthor #7
Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
201919 citationsauthor #10
Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery
201926 citationsauthor #19
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019
201980 citationsauthor #37
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019
201953 citationsauthor #35
Clinical Validation of the BREAST-Q Breast-Conserving Therapy Module
201930 citationsauthor #9
Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus
201936 citationsauthor #20
Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
201929 citationsauthor #19
Implementation of an Electronic Patient-Reported Outcome App for Health-Related Quality of Life in Breast Cancer Patients: Evaluation and Acceptability Analysis in a Two-Center Prospective Trial
201912 citationsauthor #14
Implementation of an ePRO Application for Health-Related Quality of Life (HrQoL) in Breast Cancer Patients: Evaluation and Usability Analysis (Preprint)
20190 citationsauthor #14
Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice Update Mammakarzinom 2019 Teil 2 –
20190 citationsauthor #13
Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer
201920 citationsauthor #1
Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index
20196 citationsauthor #11
Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice
201924 citationsauthor #13
Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer
201918 citationsauthor #11
Prevalence of thyroid dysfunction in metastasized breast cancer
20190 citationsauthor #7
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
201877 citationsauthor #90
Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer
201811 citationsauthor #16
Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention
201822 citationsauthor #20
Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
201820 citationsauthor #22
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer
201899 citationsauthor #88
Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer
201813 citationsauthor #4
Initial results of the FUSION-X-US prototype combining 3D automated breast ultrasound and tomosynthesis
20180 citationsauthor #13
Stimulation of chemokines in human endometrial stromal cells by tumor necrosis factor-α and interferon-γ is similar under apoptotic and non-apoptotic conditions
20185 citationsauthor #3
RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment
201820 citationsauthor #10
Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies
20189 citationsauthor #1
Initial results of the FUSION-X-US prototype combining 3D automated breast ultrasound and digital breast tomosynthesis
201820 citationsauthor #13
Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
20185 citationsauthor #15
Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient
201817 citationsauthor #12
Severe Fournier’s gangrene—a conjoint challenge of gynaecology and plastic surgery
20174 citationsauthor #3
PD-1/PD-L1 Pathway in Breast Cancer
2017166 citationsauthor #1
Metronomic Chemotherapy for Primary Non-Metastatic Breast Cancer – a Systematic Review of the Literature
20175 citationsauthor #3
Gynecologic oncologists’ attitudes and practices relating to integrative medicine: results of a nationwide AGO survey
201727 citationsauthor #17
UNC-45A is required for neurite extension via controlling NMII activation
201715 citationsauthor #7
Unfractionated Heparin Selectively Modulates the Expression of CXCL8, CCL2 and CCL5 in Endometrial Carcinoma Cells.
201612 citationsauthor #5
Abstract P4-13-06: Results of the 3rd interim analysis of the non-interventional trial BRAWO – Subanalysis of patients <70 years and ≥ 70 years
20164 citationsauthor #15
Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study
2016180 citationsauthor #13
Targeted Therapy of HER 2-Negative Breast Cancer
20161 citationsauthor #1
Targeted Therapy of HER2-Negative Breast Cancer
20164 citationsauthor #1
Abstract P4-13-08: Stomatitis in patients treated with everolimus and exemestane - Results of the 3rd interim analysis of the non-interventional trial BRAWO
20162 citationsauthor #1
Change of Patient-Reported Aesthetic Outcome Over Time and Identification of Factors Characterizing Poor Aesthetic Outcome After Breast-Conserving Therapy: Long-Term Results of a Prospective Cohort Study
201638 citationsauthor #9
Additional file 1: Table S4. of Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study
20160 citationsauthor #13
Additional file 2: Table S5. of Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study
20160 citationsauthor #13
The presence of heparins during decidualization modulates the response of human endometrial stromal cells to IL-1β in vitro
20163 citationsauthor #3
LECANDUS study (LEsion CANdidate Detection in UltraSound Data): evaluation of image analysis algorithms for breast lesion detection in volume ultrasound data
20166 citationsauthor #8
Immunological Mechanisms in Breast Cancer - from Bench to Bedside
20161 citationsauthor #2
Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer
201624 citationsauthor #8
Additional file 3: Table S6. of Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study
20160 citationsauthor #13
Abstract P4-13-07: Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER+ women - Results of the 3rd interim analysis of BRAWO
20160 citationsauthor #16
Abstract P2-02-06: Impact of apoptotic circulating tumor cells in metastatic breast cancer
20160 citationsauthor #8
Title Page / Table of Contents / Imprint / Guidelines for Authors
20150 citationsauthor #2
Long-term objective esthetic outcome after breast-conserving therapy
201551 citationsauthor #8
Bispohosphonates in the Treatment of Breast Cancer
20150 citationsauthor #4
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2015
20154 citationsauthor #2
Definition of Concepts, Formation, Objectives and Prospects of Integrative Medicine AG
20151 citationsauthor #17
Breast Cancer Treatment with Afinitor (Everolimus) and Exemestane for ER+ Women – Ergebnisse der dritten Interimsanalyse
20150 citationsauthor #12
Aromatase Inhibitors in the Prevention of Breast Cancer
20153 citationsauthor #3
Abstract P5-19-12: Subgroup analysis on efficacy in the routine treatment - Results of the 2nd interim analysis of BRAWO, the non-interventional trial "Breast Cancer Treatment with Everolimus and Exemestane for HR+ Women"
20155 citationsauthor #19
Breast Cancer Update 2014 - Focus on the Patient and the Tumour.
201511 citationsauthor #2
Emigration of tumor specific regulatory T cells from the bone marrow is triggered by S1P1 and correlates with their accumulation in breast tumors (TUM9P.1001)
20150 citationsauthor #7
Evaluation of Virtual Touch Tissue Imaging Quantification, a New Shear Wave Velocity Imaging Method, for Breast Lesion Assessment by Ultrasound
201483 citationsauthor #10
Pregnancy – A natural vaccination against tumor-associated antigens of the breast?
20140 citationsauthor #6
Recall management of patients with Rofil Medical breast implants.
20144 citationsauthor #10
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014
201413 citationsauthor #2
LBA9BREAST CANCER TREATMENT WITH EVEROLIMUS AND EXEMESTANE FOR ER+ WOMEN - RESULTS OF THE 2ND INTERIM ANALYSIS OF THE NON-INTERVENTIONAL TRIAL BRAWO
201423 citationsauthor #19
Quality of life and anxiety of patients affected by the PIP/Rofil Medical breast implant recall: results from a prospective monocentre cohort study
20141 citationsauthor #3
Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for ER+ Women – Ergebnisse der ersten Interimsanalyse der nicht-interventionellen Studie BRAWO
20140 citationsauthor #3
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014
20148 citationsauthor #4
Breast Cancer 2013 – Interpretation of New and Known Data
201324 citationsauthor #3
BRAWO - Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for ER+ Women
20130 citationsauthor #3
Breast Cancer News from ASCO 2013
20133 citationsauthor #4
Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ), a new Shear Wave Velocity Imaging Method, for Breast Lesion Assessme nt by Ultrasound Authors
20130 citationsauthor #9
Partnerships between Medical Centres and General Hospitals Providing Normal Care Standards in Gynaecology and Obstetrics in Germany.
20122 citationsauthor #1
Mammakarzinom 2012 – neue Aspekte Breast Cancer 2012 – New Aspects
20120 citationsauthor #5
Extent of Primary Breast Cancer Surgery: Standards and Individualized Concepts
201213 citationsauthor #10
Breast Cancer 2012 – New Aspects Mammakarzinom 2012 – neue Aspekte
20121 citationsauthor #5

TIMELINE

2003 51 citations

2004 0 citations

2006 113 citations

2007 3 citations

2008 2 citations

2009 3 citations

2011 0 citations

2012 55 citations

2013 27 citations

2014 132 citations

2015 75 citations

2016 275 citations

2017 217 citations

2018 318 citations

2019 395 citations

2020 161 citations

2021 217 citations

Unknown 0 citations

F. Schütz

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT